COVID-19 and Long haul COVID Resources

×

News

Advocacy News | Research News


Never miss a beat! Subscribe to our newsletter and select “Daily Digest” to get a summary of the day’s news & actions delivered to your inbox.


Photo of US ME/CFS Clinician website. Blue Banner with title at top and a question that reads What is ME/CFS?

All Doctors Should Go To This Website For ME Information!

We are thrilled to share that The US ME/CFS Clinician Coalition has launched a beautiful website to provide clinicians with expert information on the diagnosis and management of myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS). The website includes the basics of clinical management, diagnosis and management, comorbid conditions, and resources on ...

#MEAction New York Co-Hosts Free Webinar for Clinicians on September 30th!

#MEAction NY is co-sponsoring a free CME webinar Wednesday, September 30th, 2020 and we need to share widely so clinicians can know to register! DATE: Wednesday, September 30, 2020 12:00-1:00 EST Topic: Post-Viral Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): What Every Clinician Needs to Know Speaker: David Kaufman, MD, ...

James Coyne: PLOS One lawyers “squaring off” against PACE authors

Professor James Coyne has provided an update on his request to PLOS One that they enforce their data-sharing policy upon the authors of the PACE trial, who published one of their papers in the journal. Professor Coyne had requested the data from Professor Paul McCrone under PLOS One’s policy. However,

Rehmeyer and Tuller: PACE trial didn’t prove graded exercise safe for CFS

Journalists Julie Rehmeyer and Dr. David Tuller have published an analysis concluding that the PACE trial failed to demonstrate the safety of graded exercise therapy, despite its authors claiming that it was a safe treatment for patients with chronic fatigue syndrome (CFS). Their article, on Virology Blog, concludes that “the

Columbia professor says PACE damaging Lancet’s reputation

Yesterday, Columbia University professor of statistics Andrew Gelman published a warning that The Lancet was risking its reputation by refusing to rectify errors in the main paper on the PACE trial that appeared in the journal in 2011. In his article on a popular statistics blog, Professor Gelman described the

In-Depth article on ME/CFS Research Plans

MedPage Today's Update on ME/CFS Research Plans MedPage Today reposted Shannon Firth's earlier article on ME/CFS in their 2015 recap and also published an in-depth update by the author. The new article goes in-depth on Ron Davis' plans for the Big Data study and also includes an interview with Jen

David Tuller: 68 unanswered questions about the PACE trial

Yesterday, journalist and public health expert Dr. David Tuller published on Virology Blog a list of 68 questions for the authors of the controversial PACE trial. The trial studied the effects of graded exercise and cognitive therapy on chronic fatigue syndrome. Dr. Tuller has, he said, been seeking answers from

Ron Davis’ Plea for his Son’s Life

Ron Davis' Plea for his Son's Life Ron Davis recently posted a heart-felt plea for more research "before his son, and others like him, die from this horrific disease." He has given us permission to share his post in order to reach as many people as possible with Whitney's story.

Over twenty US organizations and advocates announce new working group

Help us build a powerful, participatory voice for change in Washington #MEAction is thrilled to announce that we are coming together with over twenty organizations, bloggers, and independent advocates to form a US Action Working Group. We aim to create a powerful, participatory voice for change in Congress, across our federal agencies,

NIH considering Ampligen and Rituximab trials

Basic research and drug trials under discussion at the NIH In October, the National Institutes of Health (NIH) announced it was stepping up its commitment to ME/CFS and would be expanding its intramural and extramural research programs. Francis Collins, director of the NIH, told Science that his colleagues were “determined to

NIH To Shift Funding Priorities: Will ME/CFS Benefit?

The NIH is changing how it decides to fund research. Will it benefit ME/CFS?

Davis, Tuller, Racaniello, and Levin issue FOI request for PACE data

Yesterday four scientists, led by world-famous geneticist Professor Ronald Davis, added to the pressure for scientific transparency on the PACE trial by making a request for raw data under the Freedom of Information Act. Davis was accompanied in his request by biostatistician Professor Bruce Levin and immunologist Professor Vincent Racaniello, both

PLOS One posts “notification” of intent to evaluate James Coyne’s PACE data request

PLOS One today published a statement that its staff were evaluating Professor James Coyne’s request for data from a PACE trial paper published in the journal in 2012. Professor Coyne said on social media that the move “represents progress”. King’s College London had denied Professor Coyne’s request on behalf of

What the CDC needs to know about the $5.4 million funding restoration

In a budget agreement announced early Wednesday morning, funding for the US Centers for Disease Control's (CDC) ME/CFS program was restored to the full $5.4 million. The omnibus budget bill is expected to pass both houses on Friday. CDC funding for ME/CFS had previously been cut to $0 in the proposed 2016 budget. [pullquote